Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

NCT00777153

Recurrent Glioblastoma

COMPLETED PHASE3

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00937482

Male Breast Cancer Stage IV Breast Cancer Stage IV Melanoma +7 more

TERMINATED PHASE1

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

NCT00979862

Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma +1 more

COMPLETED PHASE1

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00662506

Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma

COMPLETED PHASE1/PHASE2

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069

Glioblastoma Multiforme, Adult

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Glioblastoma Brain Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Lomustine + Cediranib (AZD2171)

Group Type EXPERIMENTAL

Cediranib

Intervention Type DRUG

oral tablet

Lomustine

Intervention Type DRUG

oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cediranib

oral tablet

Intervention Type DRUG

Lomustine

oral capsule

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RECENTIN™ AZD2171 CCNU CeeNU®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary recurrent malignant brain tumour for whom lomustine would be standard therapy - diagnosis \& stage
* Patients received no more than 2 previous systemic chemotherapy regimes
* Life Expectancy \> 12 weeks
* Patients must be at least 3 months from the completion of cranial radiation therapy